Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

David R Freyer¹, Penelope R Brock², Kay W Chang³, L Lee Dupuis⁴, Sidnei Epelman⁵, Kristin Knight⁶, Denise Mills⁷, Robert Phillips⁸, Emma Potter⁹, Demie Risby¹⁰, Philippa Simpkin¹¹, Michael Sullivan¹², Sandra Cabral¹³, Paula D Robinson¹³, Lillian Sung¹⁴

Affiliations

¹ Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Departments of Pediatrics and Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, US.
² Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK.
³ Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, CA, USA.
⁴ Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada; Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
⁵ Department of Pediatric Oncology, Casa de Saude Santa Marcelina, Sao Paolo, Brazil.
⁶ Pediatric Audiology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA.
⁷ Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada; Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
⁸ Department of Haematology and Oncology, Leeds Teaching Hospital, NHS Trust, Leeds, UK; Centre for Reviews and Dissemination, University of York, York, UK.
⁹ Division of Oncology, Royal Marsden Hospital, London, UK.
¹⁰ Great Ormond Street Hospital, London, UK.
¹¹ London, UK.
¹² Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.
¹³ Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
¹⁴ Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada. Electronic address: lillian.sung@sickkids.ca.

PMID: 31866182
PMCID: PMC7521149
DOI: 10.1016/S2352-4642(19)30336-0

Review

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

David R Freyer et al. Lancet Child Adolesc Health. 2020 Feb.

. 2020 Feb;4(2):141-150.

doi: 10.1016/S2352-4642(19)30336-0. Epub 2019 Dec 19.

Authors

Affiliations

¹ Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Departments of Pediatrics and Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, US.
² Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK.
³ Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, CA, USA.
⁴ Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada; Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
⁵ Department of Pediatric Oncology, Casa de Saude Santa Marcelina, Sao Paolo, Brazil.
⁶ Pediatric Audiology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA.
⁷ Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada; Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
⁸ Department of Haematology and Oncology, Leeds Teaching Hospital, NHS Trust, Leeds, UK; Centre for Reviews and Dissemination, University of York, York, UK.
⁹ Division of Oncology, Royal Marsden Hospital, London, UK.
¹⁰ Great Ormond Street Hospital, London, UK.
¹¹ London, UK.
¹² Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.
¹³ Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
¹⁴ Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada. Electronic address: lillian.sung@sickkids.ca.

PMID: 31866182
PMCID: PMC7521149
DOI: 10.1016/S2352-4642(19)30336-0

Abstract

Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplatin infusion duration. Regarding systemic sodium thiosulfate, the panel made a strong recommendation for administration in non-metastatic hepatoblastoma, a weak recommendation for administration in other non-metastatic cancers, and a weak recommendation against its routine use in metastatic cancers. Amifostine, sodium diethyldithiocarbamate, and intratympanic therapy should not be routinely used. Cisplatin infusion duration should not be altered as a means to reduce ototoxicity. Further research to determine the safety of sodium thiosulfate in patients with metastatic cancer is encouraged.

PubMed Disclaimer

Figures

See this image and copyright information in PMC

References

1. Public Health Agency of Canada. Cancer in young people in Canada: a report from the Enhanced Childhood Cancer Surveillance System 2017. https://www.canada.ca/en/health-canada/services/publications/ science-research-data/cancer-young-people-canada-surveillance-2017. html (accessed June 1, 2019). - PubMed
1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–82. - PubMed
1. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30: 2408–17. - PMC - PubMed
1. Knight KR, Chen L, Freyer D, et al. Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): a report from the Children’s Oncology Group. J Clin Oncol 2017; 35: 440–45. - PMC - PubMed
1. Laurell G, Bagger-Sjöbäck D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 1991; 20: 158–67. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

Affiliations

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical